FDA allows use of peramivir in some H1N1 flu patients

The FDA has issued an emergency-use authorization that allows doctors to administer peramivir, an antiviral drug developed by BioCryst Pharmaceuticals, in patients with H1N1 influenza. The approval limits the use of the product to patients who do not respond to Tamiflu or Relenza.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA